Form 4: Bio-Rad Executive Reports RSU Vesting and New Grant

Colleen Corey, Bio-Rad's EVP of Global Human Resources, reported the vesting of 576 restricted stock units and the grant of 2,740 new units.

Summary

• Colleen Corey, EVP, Global Human Resources at Bio-Rad Laboratories, Inc., reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On September 6, 2025, 576 shares of Class A Common Stock were acquired due to the vesting of restricted stock units.
• Concurrently, 209 shares of Class A Common Stock were disposed of at a price of $295.43 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, the reporting person beneficially owns 19,550 shares of Bio-Rad Class A Common Stock.
• On September 5, 2025, 2,740 new Restricted Stock Units were acquired. Each RSU represents a contingent right to receive one share of Bio-Rad Class A Common Stock.
• On September 6, 2025, 576 Restricted Stock Units were disposed of as they vested and converted into common stock.
• After these transactions, the reporting person beneficially owns 2,740 newly granted Restricted Stock Units and 1,728 Restricted Stock Units from previous grants.
• The Restricted Stock Units vest over four years at 25% per year on the yearly anniversary date of the grant.

Sentiment

Score: 5

Explanation: The filing reports routine executive compensation transactions (RSU vesting, tax-related sales, and new RSU grants) which are neutral in terms of company performance or outlook.

Positives

• Acquisition of 576 shares of Class A Common Stock through the vesting of restricted stock units, representing earned compensation.
• Grant of 2,740 new Restricted Stock Units, indicating continued long-term incentive compensation for the executive.

Negatives

• Disposition of 209 shares of Class A Common Stock at $295.43, likely for tax withholding purposes, which reduces direct share ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor, as these are routine compensation-related transactions and do not indicate a change in company fundamentals or strategy. The slight increase in outstanding shares from RSU conversion is negligible.
• Employees: Reflects standard executive compensation practices, which may influence employee perception of fairness in compensation structures.

Next Steps

• Future vesting of the 2,740 Restricted Stock Units over four years at 25% per year on the yearly anniversary date of the grant.
• Future vesting of the remaining 1,728 Restricted Stock Units from previous grants.

Key Dates

Keywords

Bio-Rad, BIO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Stock Vesting, Share Acquisition, Share Disposition